Jaguar Health, Inc. 8-K/A

What Happened

• Jaguar Health, Inc. announced it entered into Securities Purchase Agreements with two accredited investors and issued $350,000 aggregate principal of unsecured promissory notes on January 6, 2026 (transaction closed that day). The Company filed the 8-K on January 12, 2026.
• The Notes bear interest at 6.0% per annum, mature one month after issuance, are prepayable without penalty, and are unsecured. As inducement, the investors received warrants to purchase up to 350,000 shares of common stock.

Key Details

• Aggregate principal: $350,000 issued to two accredited investors; closed January 6, 2026.
• Note terms: 6% annual interest, one-month maturity, unsecured, prepayable without penalty.
• Warrants: exercisable immediately for up to 350,000 common shares at $1.00 per share (adjustable for stock splits, etc.); expire on the earlier of five years, a fundamental transaction, or a liquidation event.
• Use of proceeds: working capital and general corporate purposes.

Why It Matters

• This filing documents short-term financing that increases Jaguar Health’s near-term obligations (notes due in one month) while providing immediate cash for operating needs.
• The issued warrants represent potential future dilution of common shares if exercised (350,000 shares at a $1.00 exercise price).
• Retail investors should note the short maturity of the debt and monitor any repayment, refinancing actions, or warrant exercises, as those events affect the company’s cash needs and share count.